Evidence map›Paper›PMID 41417419›Full record

ArticleClinical journal of gastroenterology2026

Cytomegalovirus-associated ulceration complicating immune checkpoint inhibitor-related colitis.

Michiko Yamada, Tomoyuki Abe, Seiyu Kubota, Shota Chiba, Seiya Saito, Makoto Usami, Michihiro Ono, Masahiro Maeda, Miri Fujita

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Clinical journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Michiko YamadaDepartment of Gastroenterology, Steel Memorial Muroran Hospital, 1-45 Chiribetsu-Cho, Muroran-Shi, Hokkaido, 050-0076, Japan. michiko.yamada.med@gmail.com.ORCID http://orcid.org/0009-0000-9765-5473
Tomoyuki AbeDepartment of Gastroenterology, Steel Memorial Muroran Hospital, 1-45 Chiribetsu-Cho, Muroran-Shi, Hokkaido, 050-0076, Japan.
Seiyu KubotaDepartment of Gastroenterology, Steel Memorial Muroran Hospital, 1-45 Chiribetsu-Cho, Muroran-Shi, Hokkaido, 050-0076, Japan.
Shota ChibaDepartment of Gastroenterology, Steel Memorial Muroran Hospital, 1-45 Chiribetsu-Cho, Muroran-Shi, Hokkaido, 050-0076, Japan.
Seiya SaitoDepartment of Gastroenterology, Steel Memorial Muroran Hospital, 1-45 Chiribetsu-Cho, Muroran-Shi, Hokkaido, 050-0076, Japan.
Makoto UsamiDepartment of Gastroenterology, Steel Memorial Muroran Hospital, 1-45 Chiribetsu-Cho, Muroran-Shi, Hokkaido, 050-0076, Japan.
Michihiro OnoDepartment of Gastroenterology, Steel Memorial Muroran Hospital, 1-45 Chiribetsu-Cho, Muroran-Shi, Hokkaido, 050-0076, Japan.
Masahiro MaedaDepartment of Gastroenterology, Steel Memorial Muroran Hospital, 1-45 Chiribetsu-Cho, Muroran-Shi, Hokkaido, 050-0076, Japan.
Miri FujitaDepartment of Pathology and Clinical Laboratory, Steel Memorial Muroran Hospital, Muroran, Hokkaido, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a case of cytomegalovirus (CMV)-associated rectal ulceration that developed as a secondary complication of immune checkpoint inhibitor-induced colitis. A 74-year-old man who received pembrolizumab for metastatic squamous cell carcinoma of the lung developed severe immune-related colitis and required high-dose corticosteroid therapy. Although his condition initially improved, his symptoms recurred approximately four weeks after the initiation of steroid tapering. Colonoscopy revealed a circumferential, band-shaped ulcer located just above the dentate line, and a histopathological examination demonstrated nuclear inclusion bodies suggestive of CMV infection. The diagnosis was confirmed by immunohistochemical staining. Treatment with valganciclovir resulted in complete clinical and virological remission within four weeks. This case highlights the need for monitoring opportunistic infections during immunosuppressive therapy for immune-related adverse events (irAEs). It also underscores the importance of early recognition and prompt intervention for clinical deterioration.

Indexed as

Antibodies, Monoclonal, HumanizedColitisCytomegalovirus InfectionsImmune Checkpoint InhibitorsUlcerAgedAntiviral AgentsCarcinoma, Squamous CellHumansLung NeoplasmsMaleValganciclovirAntibodies, Monoclonal, HumanizedAntiviral AgentsImmune Checkpoint InhibitorspembrolizumabValganciclovirCytomegalovirus colitisImmune-related adverse eventsImmunosuppressive therapyOpportunistic infectionsRectal ulcer

Identifiers

PMID41417419

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.